Indications for Use:

RespirSalph^® Air is indicated for adults and children aged 12 years and older.

This medication is intended for regular treatment of bronchial asthma when combination therapy with a long-acting bronchodilator (beta2-agonist) and an inhaled corticosteroid is indicated:

• For patients who do not achieve adequate asthma control with an inhaled corticosteroid alone when used intermittently with a short-acting bronchodilator (beta2-agonist);
• For patients who achieve asthma control with an inhaled corticosteroid in combination with a long-acting bronchodilator (beta2-agonist);
• As initial maintenance therapy for patients with persistent asthma who require an inhaled corticosteroid for disease control.

RespirSalph^® Air is also indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients with a forced expiratory volume in one second (FEV1) of less than 60% of normal before bronchodilator therapy, and who have a history of repeated exacerbations despite regular bronchodilator treatment.

Included in the Essential Medicines List.